Dave Kuo - Pardes Biosciences VP HR
| PRDSDelisted Stock | USD 2.14 0.01 0.47% |
Insider
Dave Kuo is VP HR of Pardes Biosciences
| Phone | 415 649 8758 |
| Web | https://www.pardesbio.com |
Pardes Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.2649) % which means that it has lost $0.2649 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4028) %, meaning that it created substantial loss on money invested by shareholders. Pardes Biosciences' management efficiency ratios could be used to measure how well Pardes Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Kenneth JD | Century Therapeutics | N/A | |
| CPA CPA | NextCure | 61 | |
| Iraj Ali | Achilles Therapeutics PLC | 49 | |
| MBA BS | CytomX Therapeutics | 45 | |
| AO FRACP | Assembly Biosciences | 65 | |
| Shane Williams | Century Therapeutics | N/A | |
| Gary Hattersley | Nuvation Bio | 57 | |
| Andrew MBA | Shattuck Labs | 38 | |
| Abhinav Shukla | Shattuck Labs | ||
| Thomas Templeman | Nuvation Bio | 60 | |
| Fatima MD | Shattuck Labs | N/A | |
| Michael MBA | Champions Oncology | N/A | |
| Mark Wallet | Century Therapeutics | N/A | |
| Sandeep MD | Instil Bio | 55 | |
| Timothy Moore | Instil Bio | 63 | |
| David MD | Nuvation Bio | 54 | |
| Robert MBA | Eliem Therapeutics | 56 | |
| W Vernon | Nuvation Bio | 65 | |
| Lieping MD | NextCure | 67 | |
| Raul Collazo | Connect Biopharma Holdings | N/A | |
| Oleg Nodelman | Nuvation Bio | 44 | |
Management Performance
| Return On Equity | -0.4 | |||
| Return On Asset | -0.26 |
Pardes Biosciences Leadership Team
Elected by the shareholders, the Pardes Biosciences' board of directors comprises two types of representatives: Pardes Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pardes. The board's role is to monitor Pardes Biosciences' management team and ensure that shareholders' interests are well served. Pardes Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pardes Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Elizabeth JD, Gen Sec | ||
| Heidi CPA, Chief Officer | ||
| Dave Kuo, VP HR | ||
| Uri MD, Founder Director | ||
| Valdas Jurkauskas, VP Operations | ||
| Thomas Wiggans, CEO Chairman | ||
| Patrick OBrien, VP Relations | ||
| Sean Brusky, Chief Officer | ||
| Brian PharmD, Chief Officer | ||
| Ann Kwong, Ex Research |
Pardes Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pardes Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.4 | |||
| Return On Asset | -0.26 | |||
| Current Valuation | (22.1 M) | |||
| Shares Outstanding | 62.01 M | |||
| Shares Owned By Insiders | 13.47 % | |||
| Shares Owned By Institutions | 72.05 % | |||
| Number Of Shares Shorted | 874.35 K | |||
| Price To Book | 0.37 X | |||
| EBITDA | (99.82 M) | |||
| Net Income | (96.63 M) |
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Consideration for investing in Pardes Stock
If you are still planning to invest in Pardes Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Pardes Biosciences' history and understand the potential risks before investing.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |